131 related articles for article (PubMed ID: 8218503)
21. Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites.
Hurteau J; Rodriguez GC; Whitaker RS; Shah S; Mills G; Bast RC; Berchuck A
Cancer; 1994 Jul; 74(1):93-9. PubMed ID: 8004589
[TBL] [Abstract][Full Text] [Related]
22. Epithelial-mesenchymal transition in ovarian cancer.
Vergara D; Merlot B; Lucot JP; Collinet P; Vinatier D; Fournier I; Salzet M
Cancer Lett; 2010 May; 291(1):59-66. PubMed ID: 19880243
[TBL] [Abstract][Full Text] [Related]
23. Expression and action of transforming growth factor beta (TGFbeta1, TGFbeta2, TGFbeta3) in normal bovine ovarian surface epithelium and implications for human ovarian cancer.
Nilsson E; Doraiswamy V; Parrott JA; Skinner MK
Mol Cell Endocrinol; 2001 Sep; 182(2):145-55. PubMed ID: 11514049
[TBL] [Abstract][Full Text] [Related]
24. The role for transforming growth factor-beta (TGF-beta) in human cancer.
Gold LI
Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor-alpha acts as an autocrine growth factor in ovarian carcinoma cell lines.
Stromberg K; Collins TJ; Gordon AW; Jackson CL; Johnson GR
Cancer Res; 1992 Jan; 52(2):341-7. PubMed ID: 1309440
[TBL] [Abstract][Full Text] [Related]
26. Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line.
Hasina R; Matsumoto K; Matsumoto-Taniura N; Kato I; Sakuda M; Nakamura T
Br J Cancer; 1999 Aug; 80(11):1708-17. PubMed ID: 10468286
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2.
Duan S; Dong X; Hai J; Jiang J; Wang W; Yang J; Zhang W; Chen C
Biomed Pharmacother; 2018 Nov; 107():712-720. PubMed ID: 30138893
[TBL] [Abstract][Full Text] [Related]
28. Regulation of transforming growth factor alpha gene expression in an ovarian surface epithelial cell line derived from a human carcinoma.
Jindal SK; Ishii E; Letarte M; Vera S; Teerds KJ; Dorrington JH
Biol Reprod; 1995 May; 52(5):1027-37. PubMed ID: 7626702
[TBL] [Abstract][Full Text] [Related]
29. [Alterations of c-Myc and c-erbB-2 genes in ovarian tumours].
Pastor T; Popović B; Gvozdenović A; Boro A; Petrović B; Novaković I; Puzović D; Luković L; Milasin J
Srp Arh Celok Lek; 2009; 137(1-2):47-51. PubMed ID: 19370966
[TBL] [Abstract][Full Text] [Related]
30. Transforming growth factor-beta in cancer and metastasis.
Jakowlew SB
Cancer Metastasis Rev; 2006 Sep; 25(3):435-57. PubMed ID: 16951986
[TBL] [Abstract][Full Text] [Related]
31. Potential role of growth factors in ovarian cancer.
Jassoni VM; Amadori A; Gentile G; Alesi L
Front Biosci; 1996 Dec; 1():g14-9. PubMed ID: 9159261
[TBL] [Abstract][Full Text] [Related]
32. Expression and action of transforming growth factor alpha in normal ovarian surface epithelium and ovarian cancer.
Doraiswamy V; Parrott JA; Skinner MK
Biol Reprod; 2000 Sep; 63(3):789-96. PubMed ID: 10952922
[TBL] [Abstract][Full Text] [Related]
33. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer.
Sunde JS; Donninger H; Wu K; Johnson ME; Pestell RG; Rose GS; Mok SC; Brady J; Bonome T; Birrer MJ
Cancer Res; 2006 Sep; 66(17):8404-12. PubMed ID: 16951150
[TBL] [Abstract][Full Text] [Related]
34. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.
Havrilesky LJ; Hurteau JA; Whitaker RS; Elbendary A; Wu S; Rodriguez GC; Bast RC; Berchuck A
Cancer Res; 1995 Feb; 55(4):944-8. PubMed ID: 7531618
[TBL] [Abstract][Full Text] [Related]
35. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines.
Hu W; Wu W; Nash MA; Freedman RS; Kavanagh JJ; Verschraegen CF
Anticancer Res; 2000; 20(2A):729-33. PubMed ID: 10810347
[TBL] [Abstract][Full Text] [Related]
36. Invasion of ovarian cancer cells is induced byPITX2-mediated activation of TGF-β and Activin-A.
Basu M; Bhattacharya R; Ray U; Mukhopadhyay S; Chatterjee U; Roy SS
Mol Cancer; 2015 Aug; 14():162. PubMed ID: 26298390
[TBL] [Abstract][Full Text] [Related]
37. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
Chien CH; Huang CC; Lin YH; Shen J; Chow SN
Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
[TBL] [Abstract][Full Text] [Related]
38. Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
Hempel N; How T; Dong M; Murphy SK; Fields TA; Blobe GC
Cancer Res; 2007 Jun; 67(11):5231-8. PubMed ID: 17522389
[TBL] [Abstract][Full Text] [Related]
39. Peptide growth factors in the prostate as mediators of stromal epithelial interaction.
Byrne RL; Leung H; Neal DE
Br J Urol; 1996 May; 77(5):627-33. PubMed ID: 8689101
[TBL] [Abstract][Full Text] [Related]
40. [Growth factors and oncogenes in development and carcinogenesis. Role of the epidermal growth factor system].
Paci A; Ciarimboli G; Ferdeghini M
Minerva Med; 1994 Sep; 85(9):467-90. PubMed ID: 7936369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
